Biochemical and Phenotypical Aspects of Smith-Lemli-Opitz Syndrome and Related Disorders of Cholesterol Metabolism
NCT05047354 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 250
Last updated 2026-03-02
Summary
Background:
Smith-Lemli-Opitz Syndrome (SLOS) is a genetic disorder. It can cause birth defects and developmental delays. There is no cure for SLOS or other inherited diseases related to cholesterol production or storage. The data gained in this study may help researchers find ways to measure how well future treatments work.
Objective:
To learn more about SLOS and related disorders and how these diseases affect participants and relatives.
Eligibility:
People of any age who have or are suspected to have SLOS or another inherited disease related to cholesterol production or storage. Relatives are also needed.
Design:
Participants will be screened with a medical record review.
Participants will have visits every 6 to 12 months. They will have a physical exam. They will fill out a survey about their medical and behavioral history. They may have an eye exam. They may have a neurodevelopmental assessment. They may have a hearing test. Their outer and middle ears may be examined. Their ability to speak, understand speech, eat, and swallow may be assessed. They may get X-rays while they chew and swallow. Their functional ability and needs for adaptive devices or braces may be assessed. They may have a lumbar puncture. Photographs may be taken of their face and body.
Participants who cannot visit the NIH and relatives will have a virtual visit once a year. They will talk about their medical history and symptoms. They give blood, urine, and skin samples at a lab near their home. They will fill out a survey about their medical and behavioral history.
Participation will last for several years.
Conditions
- Smith Lemli Opitz Syndrome
- CHILD Syndrome
- Lathosterolosis
- Desmosterolosis
Sponsors & Collaborators
-
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
lead NIH
Principal Investigators
-
Forbes D Porter, M.D. · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Eligibility
- Min Age
- 1 Day
- Max Age
- 100 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2021-06-23
- Primary Completion
- 2031-05-31
- Completion
- 2031-05-31
Countries
- United States
Study Locations
More Related Trials
-
Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)
NCT01773278 ·Status: RECRUITING ·Phase: PHASE2
-
Natural History of Sphingosine Phosphate Lyase Insufficiency Syndrome (SPLIS)
NCT06669949 ·Status: RECRUITING
-
Longitudinal Studies of the Glycoproteinoses
NCT01891422 ·Status: COMPLETED
-
The Natural History of Infantile Globoid Cell Leukodystrophy
NCT00983879 ·Status: COMPLETED
-
Investigating Lysosomal Storage Diseases in Minority Groups
NCT02120235 ·Status: UNKNOWN
-
Evaluation of Biochemical Markers and Clinical Investigation of Niemann-Pick Disease, Type C
NCT00344331 ·Status: RECRUITING
-
Survey Study and Records Review of Treatment Outcomes in Freeman-Sheldon Syndrome
NCT01144741 ·Status: TERMINATED
-
Study of the Pathophysiology of RNU4ATAC and RTTN Associated Syndromes
NCT06111950 ·Status: RECRUITING ·Phase: NA
-
Thalidomide for the Treatment of Primary Sclerosing Cholangitis (PSC)
NCT00953615 ·Status: TERMINATED ·Phase: PHASE2
-
AVTX-801 D-galactose Supplementation in SLC35A2-CDG
NCT05402384 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
SPL Insufficiency Syndrome (SPLIS)/NPHS14: a SPLIS Observational Study and Patient Registry (International)
NCT04885179 ·Status: RECRUITING
-
Saccadic Eye Movements in Patients With Niemann-Pick Type C Disease
NCT00316498 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Tolerability, PK, and Efficacy Evaluation of Repeat Ascending Doses of Olipudase Alfa in Pediatric Patients <18 Years of Age With Acid Sphingomyelinase Deficiency
NCT02292654 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Combining Lovastatin and a Parent-Implemented Language Intervention for Fragile X Syndrome
NCT02642653 ·Status: COMPLETED ·Phase: PHASE4
-
Evaluating the Neurophysiologic and Clinical Effects of Single Dose Drug Challenge
NCT05418049 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Evaluation of Phenotypic Variability in Fabry Disease
NCT03145779 ·Status: WITHDRAWN
-
Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)
NCT06193928 ·Status: RECRUITING
-
A Long Term Follow-Up Study of Fabry Disease Subjects Treated With FLT190
NCT04455230 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
SLSMDS Natural History Study
NCT05029843 ·Status: UNKNOWN
-
Safety Study of Sirolimus and Hydroxychloroquine in Women With Lymphangioleiomyomatosis
NCT01687179 ·Status: COMPLETED ·Phase: PHASE1
-
24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG
NCT05549219 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, PK and PD of FLQ-101 in Premature Neonates
NCT07093255 ·Status: RECRUITING ·Phase: PHASE1
-
rhGAA in Patients With Infantile-onset Glycogen Storage Disease-II (Pompe Disease)
NCT00053573 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study to Collect Data on Fabry Disease Patients With Enhanceable Alpha-Galactosidase A Activity
NCT00106912 ·Status: COMPLETED
-
Molecular Bases of Response to Copper Treatment in Menkes Disease, Related Phenotypes, and Unexplained Copper Deficiency
NCT00811785 ·Status: COMPLETED ·Phase: PHASE3